Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious program, conolidine modulates alternate molecular targets. A Science Developments research identified that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://carlb012wsh6.wikitelevisions.com/user